The report titled “Global Anti-Migraine Drugs Market: Trends and Opportunities (2014-2019)” provides an insight into migraine drugs with a special focus on Triptans. The report also includes the market value, segmentation, types of diagnosis and treatment for migraine. It also discusses key growth drivers and upcoming trends of the market. Further, key manufacturers of anti-migraine drugs like Endo International Inc, Imapc Laboratories, GlaxoSmithKline and Pfizer Inc. are profiled in the report.
- Triptans - Ergot Alkaloids
- Endo International Inc. - IMPAX Laboratories Inc. - GlaxoSmith Kline (GSK) - Pfizer Inc.
Migraine, a condition of recurring headaches and is accompanied by symptoms like nausea, vomiting, dizziness and sensitivity to light and noise ranks among the World’s Top 20 disabling medical illnesses. It is anticipated that launches of many generic migraine drugs over the next several years will steadily increase diagnosis and drug-treatment rates, leading to sustained annual global growth of anti-migraine drugs market. Other factors contributing to the growth of these drugs include awareness among the people about proper diagnosis and treatment of migraine, rise in medical expenditures and new drugs launches.
Acute migraine treatment market is dominant by Triptans and most of them are available as pills. Triptans like Sumatriptan and Zolmitriptan are also available as nasal sprays whereas rizatriptan and zolmitriptan are available as tablets that dissolve in mouth. In next 5-10 years, cost of migraine drugs is anticipated to decline due to many generic entrants as most of them are losing their patents. Growing awareness of migraine in the emerging countries and fall in prices will facilitate the growth of anti-migraine drugs market. In addition, with the development of new treatment therapies like calcitonin gene-related peptides (CGRP) receptor antagonist and BOTOX the demand for anti-migraine drugs is anticipated to grow further.
The US is the largest market for anti-migraine drugs and there are number of companies that manufacture these drugs. Major companies include Impax, Endo Pharmaceuticals, Pfizer, GlaxoSmith Kline, Nautilus and Allergan.
Our reports have been used by over 10K customers, including:
Rosacea - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Rosacea - Pipeline Review, H2 2020, provides an overview of the Rosacea (Dermatology) pipeline landscape. Rosacea is a chronic and potentially life-disruptive disorder primarily of the...
Insomnia Pharmacological Treatment Market Research Report by Treatment (Over-the-Counter Sleep Aids and Prescription Sleep Aids) - Global Forecast to 2025 - Cumulative Impact of COVID-19 Market Statistics: The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This...
Migraine Drugs Market Research Report by Therapeutic Class (Anti-Nausea Drug, Blood Pressure Lowering Medication, Ergots, Opioid Medication, and Pain Reliever), by Treatment Type (Abortive and Preventive), by Route of Administration, by Distribution - Global Forecast to 2025 - Cumulative Impact of COVID-19 Market Statistics: The...
Dysmenorrhea Disease - Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Dysmenorrhea Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Dysmenorrhea Clinical trials scenario.This report provides top line data relating to the clinical trials on Dysmenorrhea. Report...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.